Literature DB >> 6134671

Comparison of beta-adrenoceptor blockers and calcium antagonists in hypertension.

A E Doyle.   

Abstract

The calcium antagonist drug, verapamil, was compared in double-blind, double-dummy, crossover studies with two beta-adrenoceptor blocking drugs, pindolol and labetalol. All were equally effective as antihypertensive drugs in patients with mild-to-moderate hypertension. Verapamil caused a fall in blood pressure by reducing total peripheral resistance, as judged by echocardiographic studies, and had no adverse effects on airways resistance in patients with obstructive airways disease. The favorable hemodynamic effects and absence of serious side effects suggest that verapamil may be an important advance in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134671     DOI: 10.1161/01.hyp.5.4_pt_2.ii103

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Effects of calcium antagonists on adrenaline-induced hypokalaemia.

Authors:  A Mimran; J Ribstein; J Sissmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 2.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 3.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.

Authors:  J R M'Buyamba-Kabangu; B Lepira; R Fagard; P Lijnen; M Ditu; K A Tshiani; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.